Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 2, March-April, p. 307–311

Publication type: review article

Language: English

Anal Warts (Condylomata Acuminata) – Current Issues and Treatment Modalities

Jarosław Leszczyszyn1,A,D,E,F, Igor Łebski2,A,B, Lidia Łysenko3,B,C, Lidia Hirnle4,B,C, Hanna Gerber5,B,C

1 EMc Hc clinic, dublin, Republic of Ireland

2 EuroMedicare Specialist Hospital, Wrocław, Poland

3 Department of anesthesiology and Intensive Therapy, Wroclaw Medical University, Poland

4 Department of Gynecology, Obstetrics and Neonatology, Wroclaw Medical University, Poland

5 Department of cranioMaxillofacial Surgery, Wroclaw Medical University, Poland

Abstract

HPV infections are currently the most frequent cause of genital infections in the USa. Risk factors are early onset of sexual activity, multiple sexual partners, a history STds, an early age of first pregnancy and tobacco use. In the past, HPV viruses were thought to be STds, but it is now known that penetration is not necessary. Skin-to-skin or mucosa-to-mucosa contact is enough to transmit the virus, which presents high tropism for those tissues. The Papillomaviridae family includes over 120 viruses, some of which have high malignant transformation rates. The most common malignancy connected to HPV is uterine cervix cancer and anal canal cancer. The range of morphology of perianal lesions means that a thorough clinical examination is required, including an anoscopy. Therapeutic modalities often seek to eliminate macroscopic changes rather than focus on the cause of the infection, which leads to a high recurrence rate. Externally located changes can be eliminated with patient-applied treatments. Those located in the anal canal and distal end of the rectal ampulla require treatment by a qualified medical provider. due to the high recurrence rate after standard treatment, special attention has been given to vaccinations. The polyvalent vaccine includes HPV viruses with both low and high malignant transformation risk. This has led to a decrease in the rate of malignancies.

Key words

condylomata acuminata, anal canal, cryotherapy, electrosurgery, vaccination.

References (41)

  1. Baseman JG, Koutsky LA: The epidemiology of human papillomavirus infection. J clin Virol 2005, 32, Suppl 1, S16–S24.
  2. Vermud SH, Bhatta MP, Sahasrabuddhe VV: Papillomavirus infection in Infectiuos diseases by cohen J, Powderly WG, Opal SM, Mosby 2010.
  3. Weinstock H, Berman S, Cates W Jr: Sexually transmitted diseases among american youth: incidence and prevalence estimates 2000. Perspect Sex Reprod Health 2004, 36, 6–10.
  4. Cates W: Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. american Social Health association Panel. Sex Transm dis 1999, 26 (Suppl), S2–S7.
  5. Chin-Hong PV, Vittinghoff E, Cranston RD, Buchbinder S, Cohen D, Colfax G, Da Costa M, Darragh T, Hess E, Judson F, Koblin B, Madison M, Palefsky M: age-specific prevalence of anal human papillomavisrus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect dis 2004, 190, 2070–2076.
  6. Frisch M, Biggar RJ, Goedert JJ: Human papillomavirus associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl cancer Ins 2000, 92, 1500–1510.
  7. Dizon DS, Stuckey AR, Krychman ML: at Human papilloma virus, Jones & bartlett Learnig, Sudbury, Ma, USa 2012.
  8. Human papilloma viruses. In IaRc Monographs on the Evaluation of carcinogenic Risks to Human, vol90 Lyon, france: International agency for Research on cancer 2007, 209–222.
  9. Yanofsky VR, Patel RV, Goldenberg G: Genital warts – a comprehensive review. J clin aesthetic 2012, 5, 25–36.
  10. Sturegard E, Johansson H, Ekstrom J, Hasson BG, Johnsson A, Gustafsson E, Dillner J, Forslund O: Human papillomavirus typing in reporting condyloma. Sex Transm dis 2013, 40, 123–129.
  11. Elfgren K, Kalantari M, Moberger B, Hagmar B, Dillner J: a population-based five-year follow-up study of cervical human papillomavirus infection. am J Obstet Gynecol 2000, 183, 561–567.
  12. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott Dr, Rush BB, Glass AG, Schiffman M: The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) 16 and 18 and the possible utility of type-specific HPV testing in clinical practive. J Natl cancer Inst 2005, 97, 1072–1079.
  13. Lee PK, Bas Wilkins K: condyloma and other infections including human immunodeficiency virus. Surg clin N am 2010, 90, 99–112.
  14. Kodner CM, Nasraty S: Management of genital warts. am fam Physican 2004, 2335–2342.
  15. Handley JM, Horner T, Maw RD, Lawther H, Dinsmore WW: Subcutaneous interferon alpha 2a combined with cryotherapy vs cryotherapy alone in the treatment of primary anogenital warts: a randomised observer blind placebo controlled syudy. Genitourin Med 1991, 67, 297–302.
  16. Kaplan IW: condylomata acuminata. New Orleans Med Surg J 1942, 94, 388–90.
  17. Lacey CJN, Goodall RL, Rangarson Tennvall G, Maw R, Kinghorn GR, Fisk PG, Barton S, Byren I: Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect 2003, 79, 270–275.
  18. Edwards A, Atma-Ram A, Thin RN: Podophyllotoxin 0.5% v. podophyllin 20% to treat penile warts. Genitourin Med 1988, 64, 263–265.
  19. Gaspari AA: Mechanisms of action and other potential roles of an immune response modifier. cutis 2007, 79, Suppl 4, 36–45.
  20. Chuang Chi-Mu, Monie A, Hung Chien-fu, Wu T-C: Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV dNa vaccination. J biomed Sci 2010, 17, 31–40.
  21. Hackenstein H, Hagel N, Knoche A, Kranz S, Lohmeyer J, von Wulffen W, Kershaw O, Gruber AD, Bein G, Baal N: Skin TLR7 triggering promotes accumulation of respiratory dendritic cells and natural killer cells. PLoS ONE 2012, 7, e43430. doi: 10.1371/journal.pone.0043320.
  22. Baker DA, Ferris DG, Martens MG, Fife KH, Tyring SK, Edwards L, Nelson A, Ault K, Trofatter KE, Liu T, Levy S, Wu J: Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo controlled studies. Infect dis Obstet Gyn 2011, article Id 8061105, 11 pages, doi: 10.1155/2011/806105.
  23. Meltzer SM, Monk BJ, Tewari KS: Green tea catechins for treatment of external genital warts. am J Obstet Gynecol 2009, 200:233.e1-7. doi: 10.1016/j.ajog.2008.07.064.
  24. Ahn W-S, Huh S-W, Kim CM, Lim JM, Namkoong SE, Bae SM, Lee IP: Protective effects of green tea extracts (polyphenon E and EGcG ) on human cervical lesions. Eur J cancer Prev 2003, 12, 383–390.
  25. Shuterland BA, Rahman RM, Appleton I: Mechanisms of cation of green tea catechins, with a focus on ischemia-induced neurodegeneration. J Nutr biochem 2006, 17, 291–306.
  26. Tyring SK: Effect of sinecatechins on HPV-activated cell growth and induction of apoptosis. J clin aesthet dermatol 2012, 5, 34–41.
  27. Tyring SK: Effects on HPV-induced enzymes involved in inflammatory mediator generation. J clin aesth dermatol 2012, 5, 19–26.
  28. Tatti S, Stockfleth E, Beutner KR, Tawfik K, Elsasser U, Weyrauch P, Mescheder A: Polyphenon E: a new treatment for external anogenital warts. br J dermatol 2010, 162, 176–184. doi: 10.1111/j.1365-2133.2009.09375.
  29. cdc-Genital Warts – 2010 STd Treatment Guidelines, www.cdc.gov/std/treatment/2010/genital-warts.htm.
  30. Abdullah AN, Walzman M, Wade A: Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. Sex Transm dis 1993, 20, 344–345.
  31. Godley MJ, Bradbeer CS, Gellan M, Thin RN: cryotherapy compared with tricholoroacetic acid in treating genital warts. Genitourin Med 1987, 63, 390–392.
  32. Balik E, Eren T, Bugra D: a surgical approach to anogenital buschke-Loewenstein tumours (giant condyloma acuminate). acta chir belgica 2009, 109, 612–616.
  33. Paraskevas KI, Kyriakos E, Poulios V, Stathopoulos A, Tzovaras A, Briana DD: Surgical management of giant condyloma acuminatum (Suschke-Loewenstein tumor) of the perianal region. dermatol Surg 2007, 33, 638–644.
  34. Stone KM, Becker TM, Hagdu A, Kraus SJ: Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodessication. Genitourin Med 1990, 66, 16–19.
  35. Shwarz JL: HPV vaccination’s second act: promotion, competition, and compulsion. am J Public Health 2010, 100, 1841–1844.
  36. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E: Induction of immune memory following administration of prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007, 25, 4931–4939.
  37. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF Jr, Reisinger KS: Protocol 016 Study Group.: comparison of immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6,11,16 and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006, 118, 2135–2145.
  38. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castelisaque X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated wth cervical cancer. N Eng J Med 2003, 348, 518–527.
  39. Sturegard E, Johansson H, Ekstrom J, Hansson BG, Johnsson A, Gustafsson E, Dillner J, Forslund O: Human papillomavirus typing in reporting of condyloma. Sex Transm dis 2013, 40, 123–129.
  40. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, Vardas E, Moi H, Jenssen H, Hillman R, Chang Y-H, Ferris D, Rouleau D, Bryana J, Marshall B, Vuocolo S, Barr E, Radley D, Haupt R, Guris D: Efficacy of quadrivalent HPV vaccine against HPV infection disease in males. N Eng J Med 2011, 364, 401–411.
  41. Human papilloma vaccines. WHO position paper. Wkly Epidemiol Rec 2009, 84, 118–131.
© Wroclaw Medical University